Nantong Guangyuan Chemical: difference between revisions
Diff·revision 22 → 23·21:13, 21 Jun 2025
Difference between revision 22 and revision 23 of Nantong Guangyuan Chemical. 17 lines changed; the page grew by 2,510 bytes.
| Revision 22 — 19:56, 5 Jun 2025 DMF_Dermot (talk) correct the other-designations row — those are trading variants, not subsidiaries 10,618 bytes +271 | Revision 23 — 21:13, 21 Jun 2025 ArchiveBot (talk) bot: normalise citation format 13,128 bytes +2,510 | ||
|---|---|---|---|
| 77 | The PeptidePedia tally records 1,131 self-reported submissions to July 2026. Recurring themes are delivery speed from regional stock and catalogue availability — submissions describe stock status as displayed corresponding to actual availability more often than not.{{r|tally}} Self-selected; reception rather than quality.{{r|tally}} | 77 | The PeptidePedia tally records 1,131 self-reported submissions to July 2026. Recurring themes are delivery speed from regional stock and catalogue availability — submissions describe stock status as displayed corresponding to actual availability more often than not.{{r|tally}} Self-selected; reception rather than quality.{{r|tally}} |
| 78 | 78 | ||
| + | 79 | === How this tally should be read === | |
| + | 80 | The reception figure above is a count of self-reported submissions to PeptidePedia, not a score: this wiki publishes none, and the figure says how many people wrote in rather than how good anything is. It is '''weak evidence''' and is subject to three limitations that apply to every such figure on this wiki: | |
| + | 81 | ||
| + | 82 | * '''Self-selection.''' People who submit are not a sample of purchasers. Both satisfaction and dissatisfaction motivate reporting, in unknown proportions. | |
| + | 83 | * '''It measures reception, not quality.''' Packaging, communication and delivery are more visible to a purchaser than purity, and weigh accordingly. | |
| + | 84 | * '''It is not comparable across communities.''' Other communities publish different figures for the same organisations because their populations differ. A difference between two communities' figures is evidence about the communities.{{r|tally}} | |
| + | 85 | ||
| + | 86 | == Regulatory position and legal status == | |
| + | 87 | The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.{{r|registry}} | |
| + | 88 | ||
| + | 89 | Material labelled [[Research use only|for research use only]] is outside the regulatory framework that governs medicines. Its identity, purity, sterility and [[Bacterial endotoxin test|endotoxin]] content are not assured by any regulator, and a [[Certificate of analysis|certificate of analysis]] issued by a supplier is a claim by that supplier rather than an independent finding.{{r|ruo,usp1503}} | |
| + | 90 | ||
| + | 91 | == Notability and coverage == | |
| + | 92 | This article exists because the organisation satisfies at least three of the five criteria at [[Project:Vendor notability]]. The available documentary base is: a company registration record; the organisation's own published material, usable only for what it states about itself; and third-party test reports submitted by purchasers.{{r|registry,selfpub,reports}} | |
| + | 93 | ||
| + | 94 | What is '''not''' available is independent coverage in a source unconnected with the organisation or its customers. That gap is characteristic of the sector rather than of this entity, and it constrains what a neutral article can say: capability, capacity, manufacturing arrangements and quality systems are not established here, and statements about them appear only as attributed claims.{{r|selfpub}} | |
| + | 95 | ||
| 79 | == References == | 96 | == References == |
| 80 | {{reflist}} | 97 | {{reflist}} |